Free Trial
→ This AI fund posted a 34 percent annualized payout last month (From Investors Alley) (Ad)tc pixel
NASDAQ:ARCT

Arcturus Therapeutics Q3 2026 Earnings Date & Estimates

Arcturus Therapeutics logo
$12.03 -0.58 (-4.60%)
Closing price 10/13/2026 04:00 PM Eastern
Extended Trading
$12.11 +0.08 (+0.67%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcturus Therapeutics is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Arcturus Therapeutics in Q3 2026

Arcturus Therapeutics is expected to post earnings of -$0.6866 per share on revenue of $8.00 million. In the same quarter a year earlier Arcturus Therapeutics reported -$0.49 per share on revenue of $17.15 million. Arcturus Therapeutics last reported on August 7, 2026, posting -$0.84 per share and beating the -$0.9964 consensus estimate. Arcturus Therapeutics has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.6866
Expected Revenue
$8.00 million
Prior-Year EPS
-$0.49
Prior-Year Revenue
$17.15 million
Expected Revenue Growth
-53.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.84 (Beat by +$0.1564)
Last Quarter Revenue
$2.96 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Arcturus Therapeutics Q3 2026 Earnings FAQ

Arcturus Therapeutics (NASDAQ:ARCT) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Arcturus Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Arcturus Therapeutics to post earnings of -$0.6866 per share for Q3 2026.

The consensus revenue estimate for Arcturus Therapeutics is $8.00 million for Q3 2026.

Arcturus Therapeutics Earnings Headlines

Leerink Partners Forecasts Strong Price Appreciation for Arcturus Therapeutics (NASDAQ:ARCT) Stock
October 11 at 1:30 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106824
Reviewing Arcturus Therapeutics (NASDAQ:ARCT) and Precigen (NASDAQ:PGEN)
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31099011
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel
 |  Awesomely (Ad)
Wells Fargo Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
October 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4981132/wells-fargo-keeps-their-buy-rating-on-arcturus-therapeutics-arct/
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of "Moderate Buy" from Analysts
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090888
Arcturus Therapeutics (NASDAQ:ARCT) Rating Lowered to "Sell" at Wall Street Zen
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083576
See More Arcturus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arcturus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcturus Therapeutics and other key companies, straight to your email.

About Arcturus Therapeutics

Arcturus Therapeutics (NASDAQ:ARCT) is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. Headquartered in San Diego, California, the company uses its proprietary LUNAR lipid-mediated delivery platform and STX self-amplifying mRNA technology to design and deliver RNA-based therapeutics and vaccines.

The company’s research and development activities address rare diseases, infectious diseases, respiratory conditions and other areas of significant unmet medical need. Its pipeline has included mRNA-based treatments for metabolic and genetic disorders, including ornithine transcarbamylase deficiency, as well as programs designed to address cystic fibrosis and other conditions. Arcturus has also developed RNA-based vaccine candidates, including a self-amplifying mRNA COVID-19 vaccine developed in collaboration with CSL.

Arcturus was founded in 2013 and has entered into collaborations and licensing arrangements with pharmaceutical companies and other organizations to advance its technologies. The company is led by Joseph E. Payne, who serves as president and chief executive officer. Its activities are primarily focused on research, clinical development and strategic partnerships supporting the development of RNA medicines for patients worldwide.

View Arcturus Therapeutics Profile
Earnings Tools